NCT07203729 2026-03-16
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Merck Sharp & Dohme LLC
Delcath Systems Inc.
Alliance for Clinical Trials in Oncology